Lymphoma
Conditions
Brief summary
\- To evaluate the feasibility of combination chemotherapies comprising of gemcitabine-dexamethasone-oxaliplatin for patients with refractory or relapsed malignant non-Hodgkin lymphoma (NHL)
Detailed description
\- The feasibility will be evaluated in terms of objective response rate, efficacy of stem cell collection, disease-free survival, and overall survival.
Interventions
DRUGGemDOx
gemcitabine oxliplatin
Sponsors
Cooperative Study Group A for Hematology
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
15 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Patients who have refractory to first-line CHOP-like regimen * Patients who have first relapse after * first-line CHOP-like regimen * upfront autologous or allogeneic hematopoietic stem cell transplantation * Age 15 years or more * ECOG performance status ≤ 2 * Adequate bone marrow function * Adequate kidney,liver,cardiac
Exclusion criteria
* Patients who have received GEM or OX
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| objective response rate | 10/2009 |
Secondary
| Measure | Time frame |
|---|---|
| toxicities, progression-free survival, overall survival, ASCC efficacy, rate for proceeding to ASCT | 10/2009 |
Countries
South Korea
Contacts
Primary ContactYae Eun Jang
Outcome results
None listed